Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
Guardant Health Launched Shield Blood-based Screening Test For Colorectal Cancer In S. Korea
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.